Kannalife_logo_w-Tag.png
Kannalife Inc. Publishes New Research on Chemotherapy-Induced Peripheral Neuropathy
May 21, 2019 09:00 ET | Kannalife, Inc.
DOYLESTOWN, Pa., May 21, 2019 (GLOBE NEWSWIRE) -- Kannalife, Inc. (OTC:KLFE), Kannalife (“Kannalife” or “the Company”), a biopharmaceutical company leading innovation in research, development and...
Kannalife Sciences Finalizes Share Exchange Agreement with TYG Solutions Corp.
August 01, 2018 08:00 ET | Kannalife Sciences, Inc.
NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical company, is pleased to announce the completion of a share exchange...
Kannalife Sciences to be Featured in Dateline NBC Segment Covering Company’s Research on CBD-Like Molecules as Treatments for HE, CTE
May 18, 2018 09:00 ET | Kannalife Sciences, Inc.
NEW YORK, May 18, 2018 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical company, is excited to announce that the Company will be featured in a...
Kannalife Sciences CEO Dean Petkanas to Provide Presentation on Industry Advancement at 2018 Cannabinoids in Medicine Summit
April 27, 2018 10:00 ET | Kannalife Sciences, Inc.
NEW YORK, April 27, 2018 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a phyto-medical company, announced today that the Company’s CEO Dean Petkanas will be presenting at the 2018...
Neuropathix_Logo_wTag.png
Kannalife Sciences Announces Feasibility Study With Catalent Pharma Solutions for the Development of a Novel Cannabinoid Therapeutic Agent to Treat CTE and HE
February 29, 2016 09:00 ET | Kannalife, Inc.
NEW YORK, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a Phyto-Medical Company, is pleased to announce the progress of its ongoing feasibility study being performed by...
Medical Marijuana Inc Primary
Medical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Receives Publication Through American Chemical Society for KLS-13019, a Novel Cannabidiol-Derived Target Drug Candidate for Hepatic Encephalopathy
February 18, 2016 09:00 ET | Medical Marijuana Inc
SAN DIEGO, Feb. 18, 2016 (GLOBE NEWSWIRE) -- Medical Marijuana, Inc. (OTC Pink:MJNA) is pleased to announce that the Company’s portfolio investment company, Kannalife Sciences, Inc. (“Kannalife”),...
Neuropathix_Logo_wTag.png
Kannalife Sciences Announces Publication of “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, With Improved Potency, Safety and Permeability”
February 16, 2016 11:15 ET | Kannalife, Inc.
NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a Phyto-Medical Company, is pleased to announce the publication of the body of science behind KLS-13019, one of...
Neuropathix_Logo_wTag.png
Kannalife Sciences Announces Publication of “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, With Improved Potency, Safety and Permeability”
February 16, 2016 11:15 ET | Kannalife, Inc.
NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a Phyto-Medical Company, is pleased to announce the publication of the body of science behind KLS-13019, one of...
Medical Marijuana Inc Primary
Medical Marijuana, Inc. and Kannalife Sciences, Inc. Announce Joint Effort to Raise Awareness for CTE Research
December 22, 2015 13:57 ET | Medical Marijuana Inc
NEW YORK, Dec. 22, 2015 (GLOBE NEWSWIRE) -- Medical Marijuana, Inc. (OTC Pink:MJNA) is proud to announce to shareholders and the public a joint effort with investment portfolio company Kannalife...
Neuropathix_Logo_wTag.png
Kannalife Sciences, Inc. and Gridiron Cannabis Coalition, LLC Sign Binding Memorandum of Understanding
December 21, 2015 09:00 ET | Kannalife, Inc.
NEW YORK, Dec. 21, 2015 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc., a Phyto-Medical Company (“Kannalife”), announced the signing of a binding memorandum of understanding with Gridiron Cannabis...